UnitedHealth Group, Hims & Hers Health, Eli Lilly and Company, Merck & Co., Inc., Gilead Sciences, Johnson & Johnson, and Thermo Fisher Scientific are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in the development, manufacture or delivery of medical products and services—ranging from pharmaceuticals and biotechnology to medical devices, diagnostics and healthcare providers. Investors buy these equities to gain exposure to the healthcare sector’s growth potential, including breakthroughs in treatments and technologies. Because they operate in a highly regulated, research-intensive environment, medical stocks often carry risks tied to clinical trial outcomes, patent lifespans and government approval processes. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
NYSE UNH traded down $1.97 during trading on Thursday, reaching $306.90. 11,176,139 shares of the company's stock were exchanged, compared to its average volume of 7,300,839. UnitedHealth Group has a fifty-two week low of $248.88 and a fifty-two week high of $630.73. The stock has a market capitalization of $278.40 billion, a P/E ratio of 12.85, a PEG ratio of 1.45 and a beta of 0.44. The business has a 50 day moving average price of $370.86 and a 200-day moving average price of $467.96. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.85 and a quick ratio of 0.85.
Read Our Latest Research Report on UNH
Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
NYSE HIMS traded up $1.85 on Thursday, reaching $61.09. The stock had a trading volume of 43,207,932 shares, compared to its average volume of 21,448,839. Hims & Hers Health has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a market cap of $13.67 billion, a P/E ratio of 88.54, a price-to-earnings-growth ratio of 2.23 and a beta of 2.09. The firm has a fifty day moving average of $47.00 and a two-hundred day moving average of $38.75.
Read Our Latest Research Report on HIMS
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of Eli Lilly and Company stock traded down $6.96 during trading on Thursday, reaching $784.28. The company's stock had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,357. The business's 50-day moving average price is $778.55 and its 200-day moving average price is $801.58. The firm has a market cap of $743.29 billion, a PE ratio of 63.81, a P/E/G ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE MRK traded up $0.98 during midday trading on Thursday, reaching $79.26. The company's stock had a trading volume of 21,939,215 shares, compared to its average volume of 12,963,283. The company has a market cap of $199.03 billion, a P/E ratio of 11.54, a P/E/G ratio of 0.81 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.16 and a current ratio of 1.41. The business's 50 day moving average price is $78.85 and its two-hundred day moving average price is $88.82. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $134.63.
Read Our Latest Research Report on MRK
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ GILD remained flat at $108.00 during midday trading on Thursday. The company's stock had a trading volume of 11,961,413 shares, compared to its average volume of 7,763,313. The stock has a market cap of $134.34 billion, a P/E ratio of 22.74, a PEG ratio of 0.70 and a beta of 0.29. The business has a fifty day moving average of $105.93 and a 200-day moving average of $102.53. Gilead Sciences has a 52-week low of $64.86 and a 52-week high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.
Read Our Latest Research Report on GILD
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE:JNJ traded down $1.61 during midday trading on Thursday, hitting $150.77. The stock had a trading volume of 8,323,506 shares, compared to its average volume of 7,967,133. The company's 50-day moving average price is $154.06 and its 200-day moving average price is $153.67. The company has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.
Read Our Latest Research Report on JNJ
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded up $2.28 during midday trading on Thursday, hitting $392.54. The stock had a trading volume of 2,883,201 shares, compared to its average volume of 1,944,785. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a market capitalization of $148.18 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 2.06 and a beta of 0.78. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The company's 50-day moving average price is $414.12 and its 200-day moving average price is $489.73.
Read Our Latest Research Report on TMO
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
